Diversified Portfolio Par Health offers a broad range of generic medicines, APIs, and sterile injectables across multiple therapeutic areas, presenting opportunities to supply a variety of essential medicines to healthcare providers and hospitals.

Recent Product Launches The company successfully launched an authorized generic of Amitiza ahead of patent expiry, indicating strong capabilities in navigating patent landscapes and introducing high-demand generic options to market.

Regulatory Challenges Recent FDA inspections revealed significant violations at Par Health’s manufacturing facility, highlighting potential areas for process improvement and the need for trusted compliance partners to enhance quality assurance.

Leadership Growth The appointment of Norv McAndrew as EVP and Chief Legal Officer signals strategic focus on strengthening legal, regulatory, and corporate governance functions, creating opportunities for legal and compliance-related product and service collaborations.

Market Position & Revenue With an estimated revenue between one and ten billion dollars and a workforce exceeding 1,000 employees, Par Health is well-positioned to expand distribution channels and increase sales of essential generics in competitive healthcare markets.